108 Scientists have identified a new genetic fusion in a rare type of childhood brain tumour, potentially redefining how the condition is classified and diagnosed. Researchers discovered a TEAD1::NCOA2 fusion in a case of supratentorial ependymoma, a type of tumour that primarily affects young children. This finding, published in the journal Acta Neuropathologica, challenges previous assumptions about the tumour’s genetic makeup and suggests a broader spectrum of genetic variations within this category. The study, conducted by a team of neuropathologists and geneticists, involved a one-year-old girl who presented with symptoms of intracranial hypertension. Brain scans revealed a large mass in the left hemisphere, which was later identified as an ependymoma. Initial genetic testing failed to detect the common YAP1 fusion, a hallmark of this tumour type. But further analysis using RNA sequencing uncovered the presence of the TEAD1::NCOA2 fusion, a genetic anomaly previously associated with certain soft tissue tumours. Ependymomas are a rare form of brain tumour that arise from ependymal cells, which line the brain’s ventricles and spinal cord. They are categorised into different subtypes based on their genetic and molecular characteristics. Traditionally, supratentorial ependymomas have been classified based on two main gene fusions: YAP1 and ZFTA. The discovery of the TEAD1::NCOA2 fusion suggests that additional subtypes may exist, potentially influencing how these tumours are diagnosed and treated in the future. The tumour in this case exhibited features similar to the YAP1 fusion-positive ependymoma, including a well-defined structure and specific histological markers. Despite these similarities, genetic analysis placed the tumour outside the typical classification parameters. The patient underwent surgical resection of the tumour and has shown no signs of recurrence for over eight years, suggesting that this particular fusion may not significantly alter the tumour’s overall prognosis. The TEAD1::NCOA2 fusion is known to activate the HIPPO-YAP/TAZ signalling pathway, a crucial mechanism in cell growth and development. This pathway has been extensively studied in cancer biology, as it plays a role in tumour progression and resistance to treatment. The presence of this fusion in an ependymoma raises new questions about the role of transcriptional regulators in these tumours and their potential impact on treatment responses. While this discovery does not immediately change clinical practice, it highlights the need for further investigation into the genetic diversity of ependymomas. More cases will need to be studied to determine whether this fusion represents a distinct molecular subtype or an isolated variation. If confirmed as a new category, it could influence how these tumours are classified in future editions of the World Health Organization’s guidelines on central nervous system tumours. Advances in genetic sequencing are revealing previously unrecognised tumour subtypes, underscoring the complexity of brain cancers. Understanding these genetic differences may ultimately lead to more tailored treatment approaches, improving outcomes for children diagnosed with these rare tumours. Researchers continue to explore how these findings can be integrated into diagnostic frameworks, ensuring that patients receive the most accurate diagnoses and targeted treatments possible.